CAR-T Meeting 2023 | The main aims of the T2EVOLVE Consortium
Sonia Guedan, PhD, IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain, shares some insights into the T2EVOLVE Consortium, which aims to accelerate the development of CAR-T cells, increase patient access, and explore novel tools to evaluate the efficacy of these agents. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
I am inventor on patents related to CAR-T cell therapy, filed by the University of Pennsylvania and licensed to Novartis and Tmunity Therapeutics. I have received commercial research funding from Gilead. I have received lecture fees from Bristol Myers-Squibb, Roche and Gilead.
